生物Nxt解决方案和Gen-Plus签署不具约束力的LOI,以探索MS药物市场的商业协作。 
BioNxt Solutions and Gen-Plus sign non-binding LOI to explore business collaborations in MS drug market.
BioNxt Solutions Inc. & Gen-Plus GmbH & Co KG 签署不具约束力的LOI,探讨在IP、原型Dev、临床试验规划、批量制造、薄膜商业制造方面的潜在商业协作。 BioNxt Solutions Inc. & Gen-Plus GmbH & Co KG sign non-binding LOI, exploring potential business collaborations in IP, prototype dev, clinical trial planning, batch manufacturing, & thin film commercial manufacturing. BioNxt侧重于MS市场的ODF Cladribine剂量表,预计到2033年全球MS药物市场将达到41B。 BioNxt focuses on a proprietary ODF Cladribine dosage form for the MS market, with the global MS drug market expected to reach $41B by 2033. 这些公司的目标是到2025年提交国际专利申请,到2044年可能得到专利保护。 The companies aim to file international patent applications by 2025, with potential patent protection till 2044.
